Sensus Healthcare (NASDAQ:SRTS) Director Eric Sachetta Purchases 9,708 Shares of Stock

Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Eric Sachetta acquired 9,708 shares of Sensus Healthcare stock in a transaction that occurred on Wednesday, August 26th. The stock was acquired at an average cost of $3.29 per share, for a total transaction of $31,939.32. Following the purchase, the director owned 219,018 shares of the company’s stock, valued at $720,569.22. The trade was a 4.64% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Eric Sachetta also recently made the following trade(s):

• On Thursday, August 27th, Eric Sachetta bought 10,925 shares of Sensus Healthcare stock. The shares were bought at an average cost of $3.18 per share, with a total value of $34,741.50.
• On Monday, August 24th, Eric Sachetta purchased 34,697 shares of Sensus Healthcare stock. The stock was bought at an average cost of $3.25 per share, with a total value of $112,765.25.

Sensus Healthcare Price Performance

Shares of SRTS opened at $3.52 on Friday. Sensus Healthcare, Inc. has a 1 year low of $2.66 and a 1 year high of $5.49. The company has a market capitalization of $57.94 million, a price-to-earnings ratio of -3.74 and a beta of 1.10. The business has a 50-day moving average of $3.05 and a 200-day moving average of $3.52.

Sensus Healthcare (NASDAQ:SRTS) last released its earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.41). Sensus Healthcare had a negative net margin of 88.45% and a negative return on equity of 21.57%. The firm had revenue of $2.29 million for the quarter, compared to analyst estimates of $4.60 million.

Analyst Ratings Changes

SRTS has been the subject of several research analyst reports. Wall Street Zen lowered shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Lake Street Capital cut their target price on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Alliance Global Partners restated a “buy” rating on shares of Sensus Healthcare in a report on Monday, August 17th. Weiss Ratings downgraded shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, August 18th. Finally, Citigroup reiterated a “buy” rating on shares of Sensus Healthcare in a report on Friday, May 8th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $5.83.

Hedge Funds Weigh In On Sensus Healthcare

Several large investors have recently added to or reduced their stakes in the business. Rothschild Wealth LLC acquired a new position in Sensus Healthcare during the 4th quarter valued at about $500,000. Greenline Wealth Management LLC purchased a new stake in shares of Sensus Healthcare in the fourth quarter worth approximately $513,000. Ingalls & Snyder LLC bought a new position in shares of Sensus Healthcare in the fourth quarter valued at approximately $219,000. State Street Corp lifted its holdings in shares of Sensus Healthcare by 5.2% in the fourth quarter. State Street Corp now owns 69,252 shares of the company’s stock valued at $276,000 after purchasing an additional 3,400 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Sensus Healthcare during the fourth quarter valued at approximately $79,000. Institutional investors own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.